Taiwan activates $15 billion stock stabilisation fund after precipitous falls
  • April 8, 2025

Taiwan activates $15 billion stock stabilisation fund after precipitous falls

Taiwan authorised the activation of its $15 billion stock stabilisation fund on Tuesday to prop up the market after two days of sharp falls in reaction to U.S. President Donald Trump's new import tariffs. Trump last week announced that Taiwan, which runs a large trade surplus with the United States, will get a 32% tariff, sending the markets into a tailspin on Monday after they re-opened following a Thursday and Friday holiday. Taiwan's finance ministry said in a statement that the government-run National Stabilisation Fund, which has some T$500 billion ($15.15 billion) in assets that can bolster Taiwan stocks in times of crisis, had been given the go ahead to intervene in the stock market.

WD-40 (NASDAQ:WDFC) Misses Q1 Revenue Estimates
  • April 8, 2025

WD-40 (NASDAQ:WDFC) Misses Q1 Revenue Estimates

Household products company WD-40 (NASDAQ:WDFC) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 5% year on year to $146.1 million. The company’s full-year revenue guidance of $615 million at the midpoint came in 1.9% below analysts’ estimates. Its GAAP profit of $2.19 per share was 54.2% above analysts’ consensus estimates.

Tilray (NASDAQ:TLRY) Misses Q1 Revenue Estimates
  • April 8, 2025

Tilray (NASDAQ:TLRY) Misses Q1 Revenue Estimates

Cannabis company Tilray Brands (NASDAQ:TLRY) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.4% year on year to $185.8 million. The company’s full-year revenue guidance of $875 million at the midpoint came in 2% below analysts’ estimates. Its non-GAAP loss of $0 per share was significantly above analysts’ consensus estimates.

Morning Bid: Stocks take a breath, but yuan, Treasuries convulse
  • April 8, 2025

Morning Bid: Stocks take a breath, but yuan, Treasuries convulse

After a wild Monday, equity trading appears to have calmed somewhat even as the U.S.-inspired trade war ratchets up. Speculation about a devaluation of China's yuan has moved center stage along with a snapback in U.S. Treasury yields. * China refused to bow to what it called "blackmail" from the United States as a global trade war ignited by President Donald Trump's sweeping tariffs showed little sign of abating on Tuesday.

UK stocks recover after sell-off triggered by hefty tariffs
  • April 8, 2025

UK stocks recover after sell-off triggered by hefty tariffs

Markets had been unsettled by U.S. President Donald Trump's announcement of sweeping trade tariffs last week, stoking fears of a global recession. Trump said on Monday he would talk to China, Japan and other countries over the tariffs, but was not looking at a pause on the duties. Separately, data from funds network Calastone showed British investors had piled into U.S. stocks in the weeks before Trump's tariff announcement.

China Vows ‘Fight to the End’ on Tariffs as It Props Up Markets
  • April 8, 2025

China Vows ‘Fight to the End’ on Tariffs as It Props Up Markets

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergThe Irish Hot Press Is the Low-Tech Laundry Trick the World NeedsThis Skinny Mexico City Tower Is Just 14 Feet Wide on One SideHousing Agency Aims to Relocate Its DC HeadquartersTrump Order on CDFI Fund Risks Aid for Small Businesses, HousingBoston Mayor Wu Embraces Trump Resistance as Campaign Heats UpChina pledged to retaliate against Donald Trump’s latest tariff threat and mobilize

Health insurance stocks soar after boost to Medicare reimbursement rates
  • April 8, 2025

Health insurance stocks soar after boost to Medicare reimbursement rates

Medicare-focused insurer Humana led gains with a 16% jump, while other health insurers including UnitedHealth Group, Centene and CVS Health advanced between 5% and 10%. The 5.06% average increase, more than double what the government proposed in January, could help profit margins in the sector after a post-COVID surge in demand for medical procedures drove up costs.